Live Bending Spoons Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Oncotelic Therapeutics, Inc.

OTLC

Latest SEC Filings from Oncotelic Therapeutics, Inc.

  1. 1
    1

    Oncotelic Therapeutics Reports Q2 2026 Financial Results with Increased Revenue and Net Loss

    via official filing (AI summary) 2 months ago 0 comments
  2. 2
    1

    Oncotelic Therapeutics Reports $2.2 Million Net Loss in Q1 2026, Increases Operating Expenses

    via official filing (AI summary) 5 months ago 0 comments
  3. 3
    1

    Oncotelic Therapeutics Reports $249 Million Net Income for Fiscal Year 2025

    via official filing (AI summary) 6 months ago 0 comments
  4. 4
    1

    Oncotelic Therapeutics Reports Improved Net Loss of $1.1 Million for Q3 2025

    via official filing (AI summary) 11 months ago 0 comments
  5. 5
    1

    Oncotelic Therapeutics Reports Net Income of $210,000 for Q2 2025, Significant Improvement from Prior Year

    via official filing (AI summary) about 1 year ago 0 comments
  6. 6
    1

    Oncotelic Therapeutics Reports Decreased Net Loss and Focus on Strategic Partnerships

    via official filing (AI summary) over 1 year ago 0 comments
  7. 7
    1

    Oncotelic Therapeutics Reports $4.8 Million Net Loss for Fiscal Year 2024

    via official filing (AI summary) over 1 year ago 0 comments
  8. 8
    1

    Oncotelic Therapeutics Reports Significant Financial Challenges, Net Loss, and Doubt About Its Ability to Continue as a Going Concern

    via official filing (AI summary) almost 2 years ago 0 comments